Increasing Prevalence of breast cancer is expected to drive the global breast cancer market during the forecast period

Pune, India, August 2018/MRFR Press Release/- Market Research Future published a half-cooked research report on the global breast cancer market.

Market Highlights

The breast cancer market is expected to witness tremendous growth owing to the rising prevalence of breast cancer. Other key factors such as the growing obesity among women, menstrual history, change in sedentary lifestyle, not having children, socioeconomic factors, and growing consumption of unhealthy diet are contributing towards the growth of the market. Research suggests that other factors such as smoking, exposure to chemicals that can lead to cancer, and working in night shift also may increase the risk of breast cancer. However, factors such as high cost of diagnostic procedures, expensive treatments, and side effects associated with breast biopsy procedures are expected to restrict the market growth during the forecast period.

Segmentation

The breast cancer market has been segmented on the basis of product, technique type, guidance technology, and end-user. On the basis of product, the market has been classified as biopsy needles, biopsy tables, biopsy wires, and guidance systems. On the basis of technique type, the market is classified into fine needle aspiration biopsy, core needle biopsy, biopsy markers, MRI-guided core needle biopsy, incisional biopsy, excisional biopsy, wire localization, and sentinel node biopsy. Further, the core needle biopsy subsegment is segmented into stereotactic core needle biopsy, vacuum-assisted biopsy, ultrasound-guided core biopsy, and freehand core-needle biopsy. The surgical biopsy sub-segment is segmented into incisional biopsy and excisional biopsy. On the basis of guidance technology, the market is classified into ultrasound-guided, mammography-guided magnetic resonance, CT-guided biopsy, and other image-guided breast biopsy (PET and thermography). On the basis of end-user, the market is divided into hospitals, ambulatory surgical centers, diagnostic centers, and others.

Access Report @ https://www.marketresearchfuture.com/reports/breast-biopsy-market-6288

Regional Analysis

The Americas is projected to lead the breast cancer market during the forecast period. The increasing occurrences of breast cancer drive the market in this region. According to the National Cancer Institute, there will be more cases of breast cancer diagnosed in the US by 2018 compared to other cancers. National Cancer Institute (NCI) has estimated 266,120 new cases of breast cancer and 40,920 deaths in 2018.

The European market is expected to hold the second largest market share as breast cancer is most common in the UK and Belgium. The increasing research in European countries to treat breast cancer is expected to drive the market in this region.

Asia-Pacific was projected to be the fastest growing region for the global breast biopsy market in 2017 The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. This is expected to provide favorable backgrounds for the market to grow.

The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income. But the increasing prevalence of cancer in this region is expected to influence the market growth.

Key players

Some of the key players in the global breast biopsy market are Leica Biosystems, C.R. Bard Inc., NuVue Therapeutics, Argon Medical Devices, Inc., Becton, Dickinson and Company, Devicor Medical Products Inc. Hologic Inc. Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC., Johnson & Johnson, Galini SRL, Intact Medical Corporation, Conceptus INC, Hologic Inc., Karl Storz GmbH & Co. Kg, and GE Healthcare.